CureDuchenne Blog

There’s No Straight Line in Drug Development

Today’s FDA disapproval of Sarepta’s Vyondys 53 is disheartening, but a true example of just how difficult and costly the drug development process is.  We appreciate Sarepta’s efforts and dedication […]

Updates on CureDuchenne Gene Therapy Initiative

We are excited to report the progress of CureDuchenne’s Gene Therapy Initiative.  From our investment, as early as 2010, in Nationwide Children’s permanent duplication2 skipping program, to what has become […]

The Phase 3 PolarisDMD Trial Goes Global

With a flurry of recent activity, 17 trial sites are now open for enrollment. We are especially excited to share that our first international sites in Canada and Australia have […]

UT Southwestern Wellstone Symposium

We are excited about the UT Southwestern Wellstone Symposium on March 30!  Don’t forget to RSVP by March 1.  We’ll see you there!  [download id=”13142″ template=”UT Southwestern Wellstone Symposium “]